HSCS moved above its 50-day moving average on December 04, 2024 date and that indicates a change from a downward trend to an upward trend. In of 17 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 33 cases where HSCS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The 10-day moving average for HSCS crossed bullishly above the 50-day moving average on December 09, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 4 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where HSCS advanced for three days, in of 92 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 15 cases where HSCS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for HSCS moved out of overbought territory on December 10, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 similar instances where the indicator moved out of overbought territory. In of the 8 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on December 19, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on HSCS as a result. In of 40 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HSCS turned negative on December 19, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSCS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HSCS broke above its upper Bollinger Band on December 02, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HSCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.843) is normal, around the industry mean (23.300). P/E Ratio (0.000) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (126.582) is also within normal values, averaging (43.338).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, HSCS has been loosely correlated with GENE. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HSCS jumps, then GENE could also see price increases.
Ticker / NAME | Correlation To HSCS | 1D Price Change % | ||
---|---|---|---|---|
HSCS | 100% | -3.39% | ||
GENE - HSCS | 46% Loosely correlated | N/A | ||
RSLS - HSCS | 35% Loosely correlated | -2.74% | ||
HSDT - HSCS | 32% Poorly correlated | +5.49% | ||
BIAF - HSCS | 28% Poorly correlated | -2.00% | ||
PSNL - HSCS | 22% Poorly correlated | +3.48% | ||
More |